Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 22;217(8):e20192197. doi: 10.1084/jem.20192197

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Stolley et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure S3. — Evidence that medLN T_RM can participate in a secondary response. (A) In vitro proliferation of bead-enriched, Ly6C^neg medLN P14 cells compared with Ly6C⁺ P14 cells pooled from peripheral (Periph.) LNs. Left: Ly6C phenotype of medLN P14 cells before (black) and after (red) bead enrichment. Right: CTV dilution and phenotype of medLN T_RM 68 h after in vitro peptide stimulation. Data are representative of two independent experiments. (B) Congenically distinct circulating (CD103^neg CD45.1) and resident (CD103⁺ Thy1.1) memory P14 cells were sorted from the medLN using an approach obviating Thy1.1 (depleting) antibody. Host medLN CD8⁺ T cells were excluded based on CD45.2 expression. (C) Abundance of Thy1.1 and CD45.1 P14 cells in the indicated tissues 7 d after systemic LCMV infection. (D) CD103 and integrin-β7 phenotype on CD45.1 and Thy1.1 P14 cells isolated from the indicated tissues 7 and 60 d after systemic LCMV infection (n = 4). Error bars represent mean ± SEM.